Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Leukocyte Disease Clear all
Completed Phase 2 Interventional Results available

Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

NCT00345345
View directory record Official record
Conditions
T-LGL Lymphoproliferative Disorders
Interventions
Alemtuzumab (Campath)
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 13, 2026, 10:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucosal Impedance Balloon in Diagnosis and Treatment of Eosinophilic Esophagitis (EoE)

NCT02995395
View directory record Official record
Conditions
Eosinophilic Esophagitis, Healthy
Interventions
Mucosal Impedance Balloon catheter
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 13, 2026, 10:50 AM EDT
Recruiting Phase 1 Interventional

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT05877599
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
Interventions
NT-175
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

NCT02948283
View directory record Official record
Conditions
Anemia, Fatigue, Fever, Lymphadenopathy, Lymphocytosis, Night Sweats, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma, Splenomegaly, Thrombocytopenia, Weight Loss
Interventions
Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study, Ritonavir, Quality-of-Life, Questionnaire
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

NCT05757856
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
NDX-3315, NDX-3324, SPECT/CT Imaging
Drug · Diagnostic Test
Lead sponsor
NexEos Diagnostics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 13, 2026, 10:50 AM EDT
Completed No phase listed Observational

Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

NCT03262584
View directory record Official record
Conditions
Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 13, 2026, 10:50 AM EDT
Completed No phase listed Observational

Somatization, Anxiety, and Disordered Sleep in Pediatric Eosinophilic Esophagitis

NCT04309786
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
8 Years to 18 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 13, 2026, 10:50 AM EDT
Completed No phase listed Observational Results available

Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia

NCT00723073
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 13, 2026, 10:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

NCT06851559
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
41
States / cities
Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 10:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk

NCT00613158
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
20 Years to 85 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 3 Interventional

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

NCT00035425
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 13, 2026, 10:50 AM EDT
Active, not recruiting Early Phase 1 Interventional

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

NCT03910452
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Busulfan, Alemtuzumab, Cyclophosphamide, Sirolimus, Total Body Irradiation, Allogeneic peripheral blood stem cell
Drug · Radiation · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT03821038
View directory record Official record
Conditions
Sepsis, Severe
Interventions
CYT107, Placebos
Biological · Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 13, 2026, 10:50 AM EDT
Terminated No phase listed Observational

EndoFLIP Use in Upper GI Tract Stenosis

NCT02354716
View directory record Official record
Conditions
Esophageal Stricture, Eosinophilic Esophagitis, Zenkers Diverticulum, Schatzki Ring
Interventions
EndoFLIP
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

NCT02629419
View directory record Official record
Conditions
Candidiasis, Chronic Mucocutaneous
Interventions
Amphotericin B
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

NCT01823198
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Blasts Under 20 Percent of Peripheral Blood White Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
Biological · Procedure · Drug + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
7 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 13, 2026, 10:50 AM EDT
Terminated Phase 3 Interventional Results available

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

NCT03245840
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Budesonide oral suspension
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Results available

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

NCT05552508
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Walnut Creek, California • Loxahatchee Groves, Florida • Plantation, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

NCT01508936
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

NCT02190721
View directory record Official record
Conditions
Neutropenia
Interventions
tbo-filgrastim
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Jackson, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 13, 2026, 10:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Periapical Healing Following Endodontic Microsurgery With Leukocyte and Platelet Rich Fibrin (L-PRF)

NCT06545084
View directory record Official record
Conditions
Apical Periodontitis
Interventions
Leukocyte and Platelet Rich Fibrin
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 13, 2026, 10:50 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111
View directory record Official record
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
482 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 13, 2026, 10:50 AM EDT
Terminated Phase 1 Interventional

Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant

NCT00909948
View directory record Official record
Conditions
Non Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
Interventions
Fludarabine and total body irradiation, Total body irradiation
Other · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 13, 2026, 10:50 AM EDT
Completed Phase 3 Interventional

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805
View directory record Official record
Conditions
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
2 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 13, 2026, 10:50 AM EDT